Therefore, shuttling appears to be a perfect target in those scenarios where the inhibition of BCR-ABL is insufficient to promote eradication of the cancer: in the presence of BCR-ABL mutations that impair sensitivity to TKI, in the stem cell pool and in CML blast crisis/Ph+ ALL. The gene discussed is BCR; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.